Shared alterations, such as BET protein activity and BRG1 overexpression, highlight common therapeutic targets, but further studies in adult B-ALL are needed to fully define its epigenetic landscape. This evidence concerns the gene DNER and precursor B-cell acute lymphoblastic leukemia.